Replimune Group, Inc. (REPL) Free Cash Flow
Replimune Group, Inc. (REPL) free cash flow history and trends. Track FCF in Excel with MarketXLS.
Free Cash Flow Data
| Period | Free Cash Flow (USD) |
|---|---|
| 2019-03-31 | -$27.98M |
| 2020-03-31 | -$67.09M |
| 2021-03-31 | -$63.78M |
| 2022-03-31 | -$84.52M |
| 2023-03-31 | -$130.32M |
| 2024-03-31 | -$191.13M |
| 2025-03-31 | -$198.94M |
| 2026-03-31 | -$284.57M |
How REPL compares with sector peers
| Symbol | Company | Free cash flow (latest fiscal year) |
|---|---|---|
| EYPT | EyePoint Pharmaceuticals Inc. | -$243.39M |
| NVAX | Novavax Inc. | -$250.99M |
| ARVN | Arvinas Inc. | -$275.70M |
| SNDX | Syndax Pharmaceuticals Inc. | -$323.17M |
| IOVA | Iovance Biotherapeutics Inc. | -$336.24M |
These are five companies in the same sector as REPL with a comparable annual free cash flow. Each figure above is that company's most recent completed fiscal year, read from the same annual statements as the table on its own page, so the period end dates can differ between rows.
Get Replimune Group, Inc. Data in Excel
Stream real-time stock prices and financials directly into your spreadsheets with MarketXLS.
Try: =hf_Free_Cash_Flow("REPL", 2024)
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Volume |
| 2 | REPL | $14.77 | +5.12% | 2.97M |
| 3 | ||||
| 4 | ||||
| 5 |